Skip to main content

Foresite Capital Management VI LLC

13F filer · CIK 0002013341
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$643MU.S. long equity reported on 13F
Positions238 new · 2 closed
Net flow last quarter+$116MBuys minus sells
Top 10 positions weight81.5%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202623 positions
CGONCG Oncology, Inc.$168M26.20%2.68%+6.7%Q4 2024
ALMSAlumis Inc.$120M18.60%Not reportedNot reportedQ4 2024
SPTXSeaport Therapeutics, Inc.$38.7M6.02%3.32%NewQ2 2026
DNLIDenali Therapeutics Inc.$35.9M5.59%0.87%+15.4%Q3 2025
CLDXCelldex Therapeutics, Inc.$32.7M5.09%1.12%+178.5%Q1 2026
AGIOAgios Pharmaceuticals, Inc.$29.1M4.53%1.32%+49.5%Q4 2025
CRVSCorvus Pharmaceuticals, Inc.$27.4M4.26%2.18%Not reportedQ4 2024
PBLSParabilis Medicines, Inc.$27.3M4.26%0.82%NewQ2 2026
GHRSGH Research PLC$25.3M3.93%1.52%+198.1%Q1 2026
JBIOJade Biosciences, Inc.$19.7M3.07%1.40%+177.1%Q1 2026
HNGEHinge Health, Inc.$18.3M2.85%1.35%Not reportedQ2 2025
KYMRKymera Therapeutics, Inc.$16.8M2.61%0.18%Not reportedQ4 2024
ATAIAtaiBeckley Inc.$14.5M2.26%0.74%Not reportedQ1 2026
VSTMVerastem, Inc.$12M1.87%3.48%Not reportedQ2 2025
BEAMBeam Therapeutics Inc.$11.3M1.76%0.32%NewQ2 2026
NERVMinerva Neurosciences, Inc.$11M1.71%4.20%-0.1%Q1 2026
AVBPArriVent BioPharma, Inc.$10.5M1.63%0.62%NewQ2 2026
AURAAura Biosciences, Inc.$9.47M1.47%1.29%NewQ2 2026
CRNXCrinetics Pharmaceuticals, Inc.$7.93M1.23%0.20%Not reportedQ1 2026
RACCResearch Alliance Corp III$3.21M0.50%Not reportedNewQ2 2026
ZURAZura Bio Ltd$2.66M0.41%0.47%Not reportedQ1 2026
KLRAKailera Therapeutics, Inc.$826K0.13%0.03%NewQ2 2026
IRONDisc Medicine, Inc.$70.9K0.01%0.00%NewQ2 2026
Q1 2026Reported May 15, 202617 positions
CGONCG Oncology, Inc.$150M32.67%2.52%Not reportedQ4 2024
ALMSAlumis Inc.$93.6M20.33%Not reportedNot reportedQ4 2024
CNTACentessa Pharmaceuticals PLC$54.2M11.77%0.88%Not reportedQ4 2024
CRVSCorvus Pharmaceuticals, Inc.$26.8M5.82%2.18%+32.6%Q4 2024
DNLIDenali Therapeutics Inc.$23.2M5.05%0.76%+21.0%Q3 2025
AGIOAgios Pharmaceuticals, Inc.$17.8M3.86%0.88%-0.9%Q4 2025
VSTMVerastem, Inc.$16.7M3.62%3.58%+0.4%Q2 2025
KYMRKymera Therapeutics, Inc.$12.2M2.65%0.18%Not reportedQ4 2024
NERVMinerva Neurosciences, Inc.$12M2.60%4.53%NewQ1 2026
CLDXCelldex Therapeutics, Inc.$10M2.18%0.47%NewQ1 2026
ATAIAtaiBeckley Inc.$9.74M2.12%0.75%NewQ1 2026
HNGEHinge Health, Inc.$8.5M1.85%1.35%+63.3%Q2 2025
CRNXCrinetics Pharmaceuticals, Inc.$7.7M1.67%0.20%NewQ1 2026
OKUROnKure Therapeutics, Inc.$5.99M1.30%10.57%NewQ1 2026
JBIOJade Biosciences, Inc.$4.5M0.98%0.65%NewQ1 2026
GHRSGH Research PLC$4.44M0.96%0.51%NewQ1 2026
ZURAZura Bio Ltd$2.68M0.58%0.47%NewQ1 2026
Q4 2025Reported Feb 17, 202611 positions
CGONCG Oncology, Inc.$92.2M27.88%2.75%Not reportedQ4 2024
RAPTRAPT Therapeutics, Inc.$52.9M16.00%5.64%Not reportedQ4 2024
ALMSAlumis Inc.$41.5M12.53%Not reportedNot reportedQ4 2024
CNTACentessa Pharmaceuticals PLC$34.1M10.31%0.91%+3.8%Q4 2024
VSTMVerastem, Inc.$24.2M7.32%4.03%+19.9%Q2 2025
DNLIDenali Therapeutics Inc.$16.5M4.99%0.64%Not reportedQ3 2025
NTRANatera, Inc.$15.4M4.66%0.05%NewQ4 2025
AGIOAgios Pharmaceuticals, Inc.$14.4M4.36%0.91%NewQ4 2025
KYMRKymera Therapeutics, Inc.$11.4M3.44%0.18%Not reportedQ4 2024
CRVSCorvus Pharmaceuticals, Inc.$10.6M3.21%1.85%-20.2%Q4 2024
HNGEHinge Health, Inc.$6.27M1.90%0.82%Not reportedQ2 2025
Q3 2025Reported Nov 14, 202512 positions
CGONCG Oncology, Inc.$89.5M34.57%2.84%Not reportedQ4 2024
RAPTRAPT Therapeutics, Inc.$40.3M15.57%9.45%Not reportedQ4 2024
CNTACentessa Pharmaceuticals PLC$31.9M12.31%0.98%+4.8%Q4 2024
VSTMVerastem, Inc.$23.1M8.92%3.92%+104.9%Q2 2025
ALMSAlumis Inc.$16.9M6.55%Not reportedNot reportedQ4 2024
DNLIDenali Therapeutics Inc.$14.5M5.61%0.68%NewQ3 2025
CRVSCorvus Pharmaceuticals, Inc.$12.8M4.93%2.32%Not reportedQ4 2024
AKROAkero Therapeutics, Inc.$11.6M4.49%0.31%Not reportedQ4 2024
KYMRKymera Therapeutics, Inc.$8.28M3.20%0.20%Not reportedQ4 2024
HNGEHinge Health, Inc.$6.63M2.56%0.82%Not reportedQ2 2025
RNAMAvidity Biosciences, Inc.$1.74M0.67%0.03%Not reportedQ2 2025
CASIFCASI Pharmaceuticals, Inc.$1.63M0.63%6.33%+24.5%Q4 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.